MX2009009841A - Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase. - Google Patents

Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase.

Info

Publication number
MX2009009841A
MX2009009841A MX2009009841A MX2009009841A MX2009009841A MX 2009009841 A MX2009009841 A MX 2009009841A MX 2009009841 A MX2009009841 A MX 2009009841A MX 2009009841 A MX2009009841 A MX 2009009841A MX 2009009841 A MX2009009841 A MX 2009009841A
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
acute myeloid
farnesyltransferase
treatment
methods
Prior art date
Application number
MX2009009841A
Other languages
Spanish (es)
Inventor
Yixin Wang
Mitch Raponi
Hongtao Fan
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of MX2009009841A publication Critical patent/MX2009009841A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26F—PERFORATING; PUNCHING; CUTTING-OUT; STAMPING-OUT; SEVERING BY MEANS OTHER THAN CUTTING
    • B26F1/00—Perforating; Punching; Cutting-out; Stamping-out; Apparatus therefor
    • B26F1/18—Perforating by slitting, i.e. forming cuts closed at their ends without removal of material
    • B26F1/20—Perforating by slitting, i.e. forming cuts closed at their ends without removal of material with tools carried by a rotating drum or similar support
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D—WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D28/00—Shaping by press-cutting; Perforating
    • B21D28/02—Punching blanks or articles with or without obtaining scrap; Notching
    • B21D28/14—Dies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D—WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D37/00—Tools as parts of machines covered by this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Forests & Forestry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Shaping Metal By Deep-Drawing, Or The Like (AREA)

Abstract

A simple two gene expression assay, RASGRPI:APTX, with utility in diagnosing a population of acute myeloid leukemia (AML) patients who are more likely to respond to farbesyltransferase inhibition with tipifamib (RI15777. ZARNESTRA).
MX2009009841A 2007-03-12 2008-03-13 Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase. MX2009009841A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89430807P 2007-03-12 2007-03-12
PCT/US2008/056636 WO2008112749A1 (en) 2007-03-12 2008-03-13 Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase

Publications (1)

Publication Number Publication Date
MX2009009841A true MX2009009841A (en) 2009-09-24

Family

ID=39759983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009841A MX2009009841A (en) 2007-03-12 2008-03-13 Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase.

Country Status (9)

Country Link
EP (1) EP2135073A4 (en)
JP (1) JP2011512785A (en)
KR (1) KR20090113972A (en)
CN (1) CN102317772A (en)
AU (1) AU2008225130A1 (en)
BR (1) BRPI0808872A2 (en)
CA (1) CA2680909A1 (en)
MX (1) MX2009009841A (en)
WO (1) WO2008112749A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2354922B1 (en) * 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron MARKERS FOR THE SELECTION OF PERSONALIZED THERAPIES FOR THE TREATMENT OF THE C�? NCER.
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
WO2012016021A2 (en) * 2010-07-28 2012-02-02 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
CN108500115A (en) * 2018-03-08 2018-09-07 广州拓讯安防科技有限公司 A kind of novel precise form fabrication device
CN108339880A (en) * 2018-03-08 2018-07-31 佛山尘凡环保科技有限公司 A kind of high damping copper alloy material equipment of low cost
CN108326118A (en) * 2018-03-08 2018-07-27 佛山尘凡环保科技有限公司 A kind of Novel high-damping copper alloy material equipment
CN108500114A (en) * 2018-03-08 2018-09-07 广州峥航机械设备有限公司 A kind of efficiently advanced mold design and manufacturing technology equipment
CN108500113A (en) * 2018-03-08 2018-09-07 广州峥航机械设备有限公司 A kind of novel die design and fabrication technology equipment
CN108453165A (en) * 2018-03-08 2018-08-28 广州峥航机械设备有限公司 A kind of advanced mold design and manufacturing technology equipment
CN108481435A (en) * 2018-03-08 2018-09-04 广州拓讯安防科技有限公司 A kind of precision form manufacturing device
CN108465728A (en) * 2018-03-08 2018-08-31 佛山尘凡环保科技有限公司 A kind of high damping copper alloy material equipment
CN108294839A (en) * 2018-03-08 2018-07-20 广州燃烧医疗技术开发有限公司 A kind of dental implant equipment of stabilization

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040065524A (en) * 2001-10-30 2004-07-22 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 Method for assessing and treating leukemia
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer

Also Published As

Publication number Publication date
BRPI0808872A2 (en) 2014-11-11
CN102317772A (en) 2012-01-11
WO2008112749A1 (en) 2008-09-18
CA2680909A1 (en) 2008-09-18
AU2008225130A1 (en) 2008-09-18
EP2135073A1 (en) 2009-12-23
JP2011512785A (en) 2011-04-28
KR20090113972A (en) 2009-11-03
EP2135073A4 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
MX2009009841A (en) Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase.
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
MX2008014679A (en) Assays for diagnosing and evaluating treatment options for fabry disease.
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
EP4303584A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
CR9315A (en) METHODS AND SYSTEMS FOR DIAGNOSIS, FORECAST AND SELECTION OF THE TREATMENT OF LEUKEMIA
EA201100452A1 (en) TREATMENT OF INFLAMMATORY CONDITIONS
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2009025852A3 (en) Methods of using mirna for detection of in vivo cell death
NZ617520A (en) Drug selection for breast cancer therapy using antibody-based arrays
WO2008087561A3 (en) Methods and compositions for modulating the sirna and rna-directed-dna methylation pathways
WO2009025847A3 (en) Methods for diagnosis, prognosis and methods of treatment
EP2522743A3 (en) Genetic variants contributing to risk of prostate cancer
WO2011098262A3 (en) P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
AU323703S (en) Medical instrument
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2008103971A3 (en) Prostate cancer survival and recurrence
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
SG179070A1 (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
WO2010116003A3 (en) Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy
RU2010123021A (en) METHOD FOR DIAGNOSTIC OF BREAST CANCER BY RNA LEVEL OF IL-8 AND / OR IL-18 INTERLEUKIN RNA IN BLOOD PLASMA
EP2150627A4 (en) Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal